Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

The relationship between alternative medication possession ratio thresholds and outcomes: evidence from the use of glatiramer acetate.

Oleen-Burkey MA, Dor A, Castelli-Haley J, Lage MJ.

J Med Econ. 2011;14(6):739-47. doi: 10.3111/13696998.2011.618517. Epub 2011 Sep 13.

PMID:
21913796
2.

Glatiramer acetate and interferon beta-1b: a study of outcomes among patients with multiple sclerosis.

Castelli-Haley J, Oleen-Burkey MA, Lage MJ, Johnson KP.

Adv Ther. 2009 May;26(5):552-62. doi: 10.1007/s12325-009-0028-3. Epub 2009 May 14.

PMID:
19444392
3.

Cost effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis.

Earnshaw SR, Graham J, Oleen-Burkey M, Castelli-Haley J, Johnson K.

Appl Health Econ Health Policy. 2009;7(2):91-108. doi: 10.2165/11314900-000000000-00000.

PMID:
19731967
4.

Glatiramer acetate versus interferon beta-1a for subcutaneous administration: comparison of outcomes among multiple sclerosis patients.

Castelli-Haley J, Oleen-Burkey M, Lage MJ, Johnson KP.

Adv Ther. 2008 Jul;25(7):658-73. doi: 10.1007/s12325-008-0077-z. Erratum in: Adv Ther. 2008 Aug;25(8):830. Oleen-Burkey, Merry-Kay A [corrected to Oleen-Burkey, MerriKay].

PMID:
18641926
5.

Impact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort study.

Steinberg SC, Faris RJ, Chang CF, Chan A, Tankersley MA.

Clin Drug Investig. 2010;30(2):89-100. doi: 10.2165/11533330-000000000-00000.

PMID:
20067327
6.

Effects of glatiramer acetate on spasticity in previously interferon-beta-treated and treatment-naive patients with relapsing-remitting multiple sclerosis: a prospective, nonrandomized, open-label, uncontrolled, observational pilot study.

Meca-Lallana JE, de Mingo-Casado P, Amorin-Díaz M, Martínez-Navarro ML, Barreiro AF.

Clin Ther. 2010 Jun;32(6):1061-6. doi: 10.1016/j.clinthera.2010.06.005.

PMID:
20637960
7.

Outcomes and costs of patients with persistent asthma treated with beclomethasone dipropionate hydrofluoroalkane or fluticasone propionate.

Lage MJ, Gross GN, Brewster C, Spalitto A.

Adv Ther. 2009 Aug;26(8):762-75. doi: 10.1007/s12325-009-0056-z. Epub 2009 Aug 8.

PMID:
19669630
8.

Assessing the role of patient support services on adherence rates in patients using glatiramer acetate for relapsing-remitting multiple sclerosis.

Jones JL, Scheidt DJ, Kaushal RS, Carroll CA.

J Med Econ. 2013;16(2):213-20. doi: 10.3111/13696998.2012.744316. Epub 2012 Nov 8.

PMID:
23098539
9.

Medication adherence with disease modifying treatments for multiple sclerosis among US employees.

Kleinman NL, Beren IA, Rajagopalan K, Brook RA.

J Med Econ. 2010;13(4):633-40. doi: 10.3111/13696998.2010.527588. Epub 2010 Oct 19.

PMID:
20958113
10.

Impact of medication adherence to disease-modifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosis in the US.

Ivanova JI, Bergman RE, Birnbaum HG, Phillips AL, Stewart M, Meletiche DM.

J Med Econ. 2012;15(3):601-9. doi: 10.3111/13696998.2012.667027. Epub 2012 Mar 1.

PMID:
22376190
11.

Cost-effectiveness of glatiramer acetate and interferon beta-1a for relapsing-remitting multiple sclerosis, based on the CombiRx study.

Darbà J, Kaskens L, Sánchez-de la Rosa R.

J Med Econ. 2014 Mar;17(3):215-22. doi: 10.3111/13696998.2014.890936.

PMID:
24494728
12.

Drug adherence and multidisciplinary care in patients with multiple sclerosis: protocol of a prospective, web-based, patient-centred, nation-wide, Dutch cohort study in glatiramer acetate treated patients (CAIR study).

Jongen PJ, Hengstman G, Hupperts R, Schrijver H, Gilhuis J, Vliegen JH, Hoogervorst E, van Huizen M, van Munster E, Samijn J, de Schryver E, Siepman T, Tonk M, Zandbergen E, ten Holter J, van der Kruijk R, Borm G.

BMC Neurol. 2011 Mar 30;11:40. doi: 10.1186/1471-2377-11-40.

13.

Cost effectiveness and budget impact of natalizumab in patients with relapsing multiple sclerosis.

Chiao E, Meyer K.

Curr Med Res Opin. 2009 Jun;25(6):1445-54. doi: 10.1185/03007990902876040.

PMID:
19422279
14.

Glatiramer acetate and interferon beta-1a for intramuscular administration: a study of outcomes among multiple sclerosis intent-to-treat and persistent-use cohorts.

Castelli-Haley J, Oleen-Burkey MA, Lage MJ, Johnson K.

J Med Econ. 2010;13(3):464-71. doi: 10.3111/13696998.2010.496650.

PMID:
20662760
15.

Impact of co-prescribed glatiramer acetate and antihistamine therapy on the likelihood of relapse among patients with multiple sclerosis.

Ollendorf DA, Castelli-Haley J, Oleen-Burkey M.

J Neurosci Nurs. 2008 Oct;40(5):281-90.

PMID:
18856249
16.

Using observational analysis of multiple sclerosis relapse to design outcomes-based contracts for disease-modifying drugs: a feasibility assessment.

Lage MJ, Carroll CA, Fairman KA.

J Med Econ. 2013 Sep;16(9):1146-53. doi: 10.3111/13696998.2013.823868. Epub 2013 Aug 8.

PMID:
23844620
17.

Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia.

Darkow T, Henk HJ, Thomas SK, Feng W, Baladi JF, Goldberg GA, Hatfield A, Cortes J.

Pharmacoeconomics. 2007;25(6):481-96.

PMID:
17523753
18.

Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis.

Bergvall N, Petrilla AA, Karkare SU, Lahoz R, Agashivala N, Pradhan A, Capkun G, Makin C, McGuiness CB, Korn JR.

J Med Econ. 2014 Oct;17(10):696-707. doi: 10.3111/13696998.2014.940422. Epub 2014 Jul 23.

PMID:
25019581
19.

Association of cinacalcet adherence and costs in patients on dialysis.

Lee A, Song X, Khan I, Belozeroff V, Goodman W, Fulcher N, Diakun D.

J Med Econ. 2011;14(6):798-804. doi: 10.3111/13696998.2011.627404. Epub 2011 Oct 11.

PMID:
21988567
20.

Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebo-controlled clinical trials.

Martinelli Boneschi F, Rovaris M, Johnson KP, Miller A, Wolinsky JS, Ladkani D, Shifroni G, Comi G, Filippi M.

Mult Scler. 2003 Aug;9(4):349-55.

PMID:
12926839
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk